- Page 1/2
- Next Page
COMMENT
Global, aging population is one of the few long-term, indefinite themes. Definitely. In the medium- to long-term, you spend on medical devices and drugs as you age. That structural backdrop remains in place. Short-term, there are a number of catalysts such as the US election is over and vaccine development. Public and political perception is bestowing a halo effect on companies. These companies are growing earnings and have great clarity. This sector is trading at a 20-year discount to the market, and he doesn't think that's reasonable given the tailwinds.
PAST TOP PICK
(A Top Pick Jan 17/20, Down 15%) Committed to transitioning to a more pure play R&D-focused biopharmaceutical company. But it hasn't delivered. Consumer businesses are being spun out. Great vaccine business, but there's competition. OK at current valuations. Risk profile has changed. Finances will be impacted by number of vaccines actually needed.
biotechnology
pharmaceutical
COMMENT
What about investing in some of the experimental areas in biotech? There's a lot of rotation from growth in the markets, even though we're hitting new highs. It's not really going from growth to value; it's going from growth to momentum. He sees it in the small cap biotech space. Russell small cap healthcare is up about 75% compared to large cap healthcare up 9%. He prefers to look at good quality businesses with above-market earnings growth at a 20-year discount on valuation. Be aware of this when you start looking at new areas.
HOLD
Diversified large cap. A lot of businesses working really well. Celgene acquisition diversified their oncology. Main drug is performing well. Trading at 8.5x forward earnings, with low double digit EPS growth. One of his core holdings.
biotechnology
pharmaceutical
